InhaleRx (ASX:IRX) executed a study order with iNGENū CRO as the contract research organization to oversee a phase two clinical trial of its non-opioid inhaled Breakthrough Cancer Pain management alternative candidate IRX-211 for opioid-tolerant patients, according to a Thursday Australian bourse filing.
The phase two double-blind, placebo-controlled, multicenter trial will evaluate the efficacy, safety, and tolerability of IRX-211.
Breakthrough Cancer Pain is characterized by high-intensity, short-duration pain that occurs often in several episodes per day.
The trial is fully funded by a facility of up to AU$38.5 million with Clendon Biotech Capital.
It plans to file an amendment with the Human Research Ethics Committee to accommodate the new sample size and will likely consult with the US Food and Drugs Administration on the changes associated with this amendment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。